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Abstract
Objectives: The quantitation of BCR-ABL1 mRNA is man-
datory for chronic myeloid leukemia (CML) patients, and 
RT-qPCR is the most extensively used method in testing 
laboratories worldwide. Nevertheless, substantial vari-
ation in RT-qPCR results makes inter-laboratory compa-
rability hard. To facilitate inter-laboratory comparative 
assessment, an international scale (IS) for BCR-ABL1 was 
proposed.
Methods: The laboratory-specific conversion factor (CF) to 
the IS can be derived from the World Health Organization 
(WHO) genetic reference panel; however, this material 
is limited to the manufacturers to produce and calibrate 
secondary reference reagents. Therefore, we developed 
secondary reference calibrators, as lyophilized cellular 
material, aligned to the IS. Our purpose was both to re-
evaluate the CF in 18 previously harmonized laboratories 
and to propagate the IS to new laboratories.
Results: Our field trial including 30 laboratories across 
Latin America showed that, after correction of raw BCR-
ABL1/ABL1 ratios using CF, the relative mean bias was 
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significantly reduced. We also performed a follow-up of 
participating laboratories by annually revalidating the 
process; our results support the need for continuous reval-
idation of CFs. All participating laboratories also received 
a calibrator to determine the limit of quantification 
(LOQ); 90% of them could reproducibly detect BCR-ABL1, 
 indicating that these laboratories can report a consistent 
deep molecular response. In addition, aiming to investi-
gate the variability of BCR-ABL1 measurements across dif-
ferent RNA inputs, we calculated PCR efficiency for each 
individual assay by using different amounts of RNA.
Conclusions: In conclusion, for the first time in Latin 
America, we have successfully organized a harmoniza-
tion platform for BCR-ABL1 measurement that could be of 
immediate clinical benefit for monitoring the molecular 
response of patients in low-resource regions.
Keywords: BCR-ABL1; harmonization; Ph-IS; RT-qPCR.
Introduction
Residual disease in chronic myeloid leukemia (CML) 
patients undergoing therapy with tyrosine kinase inhibi-
tors (TKIs) is measured by assessing the quantity of tran-
scripts of the BCR-ABL1 fusion gene in peripheral white 
blood cells. This analysis is carried out with molecular 
tests, based on quantitative reverse-transcription PCR 
(RT-qPCR) technology; however, the wide array of pre-
analytical and analytical methods used worldwide and 
the absence of consensus guidelines have led to large var-
iations in quantitative BCR-ABL1 measurements, which 
hamper inter-laboratory comparative studies, patient 
manageability and standardized definition of treatment 
response [1]. Harmonization of the various laboratory 
procedures and reporting methods used worldwide is 
therefore essential to standardize optimal treatment 
response criteria and facilitate comparison across labo-
ratories and patients. It is now recognized that monitor-
ing BCR-ABL1 ratios on the so-called international scale 
(IS) is vital in the management of patients with CML 
and for improving outcomes. Efforts to harmonize pro-
cedures to measure BCR-ABL1 fusion transcripts have 
included important investments in sample exchange 
programs to derive laboratory-specific conversion factors 
(CFs); these efforts showed improvements in inter-labo-
ratory concordance rates, but the process is laborious 
and limited due to the lack of a common set of reference 
samples that can be shared on a global scale [2, 3]. This 
requirement was addressed in part by the formulation 
and validation of the first World Health Organization 
(WHO) International Genetic Reference Panel for quan-
titation of BCR-ABL1 by RT-qPCR [4]. The WHO primary 
standards consist of a four-level panel of e14a2-positive 
lyophilized cell line dilutions. Each level has an assigned 
IS value, which was obtained by repeated testing of each 
sample level in expert IS-standardized laboratories. 
Unfortunately, the stock of the WHO primary standards 
is limited, and their accessibility has been restricted to 
manufacturers of testing kits or secondary reference 
standards. In principle, these secondary reagents might 
be formulated in different ways, such as freeze-dried 
cells, cell lysates or synthetic RNAs, but they would need 
to be in a form that enables calibration to the IS (i.e. 
reagents for which a BCR-ABL1/control gene ratio can 
be derived). Accordingly, as recently reported by us [5], 
we developed secondary reference materials as lyophi-
lized cellular calibrators, aligned to the IS percent ratios 
through the WHO primary standards. Also, we piloted 
an international, multicenter, harmonization program 
(Ph-IS) by using five-level cellular calibrator samples. 
Based on this experience, the first in Latin America, in 
this work we report an update at 3 years of the program 
and several suggestions in order to improve accuracy in 
the quantification of BCR-ABL1.
Materials and methods
Participant laboratories
The study was conducted by a single reference laboratory, Genetic 
and Hematologic Laboratory (from here on called RefLab), belong-
ing to the IMEX (CONICET-National Academy of Medicine, Buenos 
Aires, Argentina). Thirty laboratories were invited to take part in the 
international collaborative program and were chosen because they 
routinely perform BCR-ABL1 testing. These laboratories form the 
LABS (Latin America BCR-ABL1 Standardization) group. Nineteen 
laboratories were from Argentina, while the remaining 11 labora-
tories were from Mexico, Uruguay, Paraguay, Costa Rica, Panamá, 
Peru, Colombia, Guatemala and Ecuador (Supplementary Table 1). 
The materials were analyzed in each laboratory according to its own 
RNA extraction and RT-qPCR protocol. The following data were 
recorded: date of RNA extraction, total micrograms of RNA, A260/
A280, A260/A230, BCR-ABL1 transcript value (cycle threshold [Ct] value 
and copy number) ABL1 transcript value (Ct value and copy num-
ber), BCR-ABL1/ABL1 ratio before conversion to IS (BCR-ABL1IS will 
be used to indicate BCR-ABL1/ABL1 values that have been corrected 
using the CF), and slope and efficiency of standard curves. Standard 
curves of known amounts of BCR-ABL1 and ABL1 allow calculation 
of the %ratio in the test sample. Standard curves were obtained by 
using three different types of plasmid dilutions depending on the 
RT-qPCR method employed in each laboratory; of the 31 laboratories 
(including RefLab), 15 of them used Molecular MD Kit ( MolecularMD, 
Cambridge, MA, USA), which includes a unique six-plasmid dilution 
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series (from 3 × 105 to  3 × 100) for both BCR-ABL1 and ABL1 targets. 
Twelve laboratories used Ipsogen plamids (Qiagen, Germantown, 
MD, USA) – four of them from the Ipsogen® BCR-ABL1 Mbcr IS-MMR 
DX kit, which provides a unique six-plasmid dilution series (from 
1 × 106 to 1 × 101) for both BCR-ABL1 and ABL1 targets, while the others 
eight laboratories, which employed an LDT approach, used Ipsogen 
ABL Control Gene (four Standards [from 1 × 103 to 1 × 106]) and Ipso-
gen BCR-ABL1 Mbcr Standards (5 standards [from 1 × 101 to 1 × 106]). 
The remaining four laboratories used the ERM® Certified Reference 
Material from European Commission – Joint Research Centre Insti-
tute for Reference Materials and Measurements (IRMM), which pro-
vides the six ERM-AD623 plasmid solutions (from 1.08 × 106 to 1 × 101). 
Raw data generated by the 30 participating laboratories were directly 
sent by e-mail from each site to RefLab, by using a specific form.
Reference laboratory validation
RefLab employed a one-step RT-qPCR approach based on the Mole-
cularMD kit (MRDx® BCR-ABL Test, NY, USA) and a Rotor-Gene® 
Q MDx 5plex HRM (high-resolution melting) platform (Qiagen, 
 Stockach,  Germany). RefLab obtained the WHO primary standards 
(NIBSC code 09/138) from the United Kingdom National Institute for 
Biological Standards and Control (Potters Bar, United Kingdom). 
In order to ensure the consistent performance of the entire process 
along time, two different quality control (QC) RNA samples with a 
high and low BCR-ABL1 level were processed in the same way as the 
patient samples in every run. QC samples had pre-established BCR-
ABL1 values and, for the run to be accepted, the values had to be 
within a defined range, which was based on the standard deviation 
(SD) of the analytical system. The yearly mean QC values since 2010 
are detailed in  Supplementary Table 2.
Secondary calibrator production
A total of 20 batches of cellular calibrators were independently pre-
pared according to standard operating procedures, in order to satisfy 
the need for calibrators, in the Latin American region. The samples 
were produced by serial dilution of the t(9;22)-positive cell line K562 
(expressing BCR-ABL1 e14a2 fusion transcript) in the t(9;22)-negative 
cell line HL-60. Cell lines were grown in RPMI 1640 medium (Gibco) 
supplemented with 10% (for K562) or 20% (for HL60) fetal bovine 
serum (Natocor, Cordoba, Argentina). Formulations were planned 
to target IS% ratios close to each of the established TKI clinical 
response criteria, that is, 10% (complete hematologic response), 
1% (complete cytogenetic response), 0.1% (MR3.0, major molecular 
response), and 0.01% and 0.001% (MR4.0 and MR5.0 respectively, deep 
molecular response). The last dilution is expected to be close to the 
limit of detection for most of RT-qPCR methods. Samples were stabi-
lized by lyophilization [5], in glass ampules filled with 2 × 106 cells 
(1 mL) (AdVantage-Plus freeze dryer, VIRTIS). Freeze-dried material 
was stored at −20 °C (range between −18 ° and −22 °C) and shipped 
at room temperature between 15 ° and 25 °C. Each panel of calibra-
tors (i.e. CAL-IS, Calibrator to International Scale) was labeled in 
a blinded fashion such that participating laboratories received 2 
ampoules from each of the five BCR-ABL1 expression levels (named 
CAL-IS_01 to CAL-IS_05), thus representing in total 10 blinded 
ampoules per panel. For evaluation of the homogeneity and stability, 
before dispatching, we checked that each lot met all predefined QC 
criteria for RNA yield, purity and minimum ABL1 copy number per 
PCR reaction (see Supplementary Materials and Methods). For the 
assignment of %IS reference values, each batch was evaluated in 
quintuplicate (from two randomly picked ampoules from each level 
of BCR-ABL1 expression) at the RefLab (see Supplementary Materials 
and Methods).
Peripheral blood samples
Peripheral blood samples were collected from two CML patients 
at diagnosis (Dx) before any treatment. The diagnosis of CML was 
determined through the detection of the Philadelphia chromosome 
using cytogenetic evaluation and end-point RT-PCR for BCR-ABL1. 
In each laboratory, RNA was extracted using Trizol (ThermoFisher 
Scientific, Waltham, MA, USA) following the manufacturer’s instruc-
tions. Patients provided written informed consent, and the study was 
approved by the local research Ethics Committee.
RNA input curve
For the evaluation of efficiency of the RT-qPCR assay for  BCR-ABL1 
and ABL1, each laboratory performed a curve with different amounts 
of RNA obtained from CAL-IS_03 (MR3.0), using 125 ng, 250 ng, 
500 ng and 1000 ng of RNA input per RT-qPCR reaction; three rep-
licates were run per sample at each input level. For evaluation of 
the efficiency of the method using samples from CML patients at 
Dx, each laboratory performed a curve with 250, 500 and 1000 ng 
of RNA input per RT-qPCR reaction; two replicates were run at each 
input level.
Data analysis
Laboratory-specific CFs were calculated as the antilog of the arith-
metic mean of the differences between log-transformed reference 
IS% ratios and log-transformed raw percentage ratios measured in 
each laboratory for each panel and level. All data analyses assumed 
a normal-like distribution of results after Log10 transformation of 
the percent ratios. Bias and correlation analyses were performed 
by using the Bland-Altman method and least squares linear regres-
sion analyses. Variability at individual sample levels, across mul-
tiple sample levels and in pooled analyses was assessed by using 
Log10-transformed percentage ratios before calculation of the 95% 
limits of agreement (LOA). To determine the LOA of the RefLab 
method (intrinsic method variation), RNA samples were analyzed in 
replicates within the reference laboratory encompassing variables 
such as the operator, day of analysis, reagent batches, and calibra-
tion status of the instrument and pipettes. The spread of results as 
estimated by the 95% LOA was plus or minus 2.5-fold of the mean, 
which is an indicator of within-method variability. For each method, 
the limit of quantification (LOQ) was calculated by considering the 
upper level of the SD interval from the mean. The CFIndex was calcu-
lated as the ratio between CFs derived from two consecutive rounds 
of calibration (CFn/CFn+1).
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Results
LABS group status in 2019
The whole study design comprises five principal steps 
as illustrated in Supplementary Figure 1 and previ-
ously reported by us [5]. As detailed in the Materials and 
method section, two panels of CAL-IS were sent to each 
one of the 30 clinical laboratories for evaluation (Step 4, 
Supplementary Figure 1). Each laboratory tested the panel 
with unique BCR-ABL1 assays, resulting in a total of 30 
BCR-ABL1 tests included in this report. Only Trizol RNA 
extraction method was used by following manufacturer 
indications; for 16 laboratories that employed a two-step 
approach for cDNA synthesis, two RT reactions were per-
formed for each of the extracted RNA samples on two dif-
ferent days, giving a total of 20 cDNA samples. Samples 
for BCR-ABL1 and the control gene were analyzed using 
the established RT-qPCR methods of the participating lab-
oratories. Six different types of RT-qPCR machines were 
used (Supplementary Table 1). Twelve of the participants 
used laboratory-developed test as their RT-qPCR protocol 
based on Gabert et al. [6] and Beillard et al. [7], while the 
remaining 18 laboratories used commercial kits (Supple-
mentary Table 1).
The laboratories were asked to conduct two studies 
with the secondary panel. In Study 1, in order to estimate 
the specific CF to the IS and to assess the performance of 
the BCR-ABL1 tests, each laboratory quantified CAL-IS_01 
to CAL-IS_04 on four different days, carrying out a total of 
72 RT-qPCR reactions. In Study 2, in order to determine the 
LOQ, 2 ampoules of CAL-IS_05 were tested on four differ-
ent days, carrying out a total of eight reactions.
Raw BCR-ABL1/ABL1 ratios generated in each 
laboratory were used to calculate the specific CF to IS (Step 
5, Supplementary Figure 1), as detailed in Supplementary 
materials and methods, and to assess the sensitivity, lin-
earity and precision of local RT-qPCR methods (Table 1). 
Raw percentage ratios were consistent with a 10-fold serial 
dilution and were linear for the first four levels. All labo-
ratories obtained ABL1 copy numbers above the minimum 
copy number requirements (>32,000 ABL1 copies) for 
almost all samples evaluated (less than 3% of tests were 
rejected) when considering all runs performed. Inter-lab-
oratory variability and IS standardization were assessed 
relative to nominal IS% ratios independently assigned to 
each CAL-IS by direct comparison to the WHO primary 
standards. Before harmonization, the relative mean bias 
ranged from −0.41-fold to +0.40-fold in the 30 laboratories, 
indicating a relatively wide inter-laboratory variability 
(Figure 1A). Following conversion of raw percentage ratios 
to IS% ratios using laboratory-specific CF, the relative 
mean bias ranged from −0.027-fold to +0.033-fold (Figure 
1B), indicating a significant reduction in inter-laboratory 
variability. The intra-laboratory precision was good with 
an average 95% LOA of 2.1-fold and less than 2.5-fold in 
most cases, with the corresponding level-specific mean 
CV between 6% and 45% (mean = 21%, with 26 out of 30 
laboratories with a mean CV ≤30%). In Table 1, we also 
report the last CF values for each laboratory with the cor-
responding 95% LOA, the median and the range. In total, 
75 CFs were derived if considering all laboratories.
To survey whether changes in the detection system, 
methodology, reagents or operator could cause a shift 
in the CF value, we performed a follow-up of participat-
ing laboratories by annually revalidating the process. As 
shown in Figure 2, without considering RefLab, 21 out of 
30 laboratories could repeat the entire process of harmo-
nization at least once. Of the 21 laboratories with complete 
data, nine had stable CFs (defined as a CFindex within 0.75–
1.33, green points in the graph; Figure 2), in all rounds 
of validation. Three laboratories improved their stability 
since the first CFindex calculation (a mix of red and green 
points over time); nine laboratories were outside the 
optimal range in all rounds of validations. This inconsist-
ency is also reflected by the median and range columns 
reported in Table 1; particularly, Lab #21 shows an outlier 
value due to simultaneous modification of the platform 
and methodology. These results support the need for con-
tinuous revalidation of CFs.
All participating laboratories received the fifth cali-
brator (CAL-IS_05); as expected, BCR-ABL1 was incon-
sistently detected below the linear quantitative detection 
range of the RT-qPCR method in the lowest positive 
sample. However, CAL-IS_05 is useful to calculate the 
LOQ for each method; as indicated in the Materials and 
methods section, LOQ was calculated by considering the 
upper level of the SD interval from the mean (Table 1). The 
overall BCR-ABL1 detection rate ranged from 0% (1 out of 
30 laboratories) to 100% (23 out of 30 laboratories). In 
total, 27 out of 30 laboratories (90%) could reproducibly 
detect BCR-ABL1 in CAL-IS_05; these laboratories can 
report a consistent MR4.5.
Evaluation of reverse transcription efficiency 
for target and reference genes
With the aim to investigate the variability of BCR-ABL1 
measurements across different RNA inputs, we calculated 
the PCR efficiency (Ef) for each individual BCR-ABL1 and 
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reference gene assay. Accordingly, we performed a pilot 
study including eight laboratories (seven from Argentina 
and one from Uruguay) that are part of the LABS network. 
Each laboratory performed quantification of BCR-ABL1 and 
ABL1 using four different amounts of RNA during the RT 
step (1000, 500, 250 and 125 ng). Total RNA was obtained 
from secondary calibrator samples and processed using 
the routine method in each laboratory. Evaluation of Ct 
vs. Log (RNA) for each gene gave different results depend-
ing on the laboratory, which could be grouped into three 
categories: (i) four out of eight laboratories (50%) showed 
comparable efficiencies for BCR-ABL1 and ABL1 genes, 
with values close to the ideal Ef = 100% (RefLab, Labs 
#3, #11, #12); (ii) three out of eight laboratories (38%) 
showed comparable efficiencies for BCR-ABL1 and ABL1 
genes, with values deviated from the ideal Ef (Labs #2, #4, 
#21); and (iii) one out of eight laboratories (15%) showed 
efficiencies for BCR-ABL1 and ABL1 genes that differed sig-
nificantly (Lab #16, p < 0.05) (Figure 3).
BCR-ABL1/ABL1 ratio at diagnosis
The BCR-ABL1IS transcript rate decline from baseline 
to 3 months could be more predictive than 10% IS level 
at 3  months. However, discordant results have been 
reported about the feasibility of ABL1 as an internal gene 
control, as it is not reliable for BCR-ABL1 quantification 
above 10% [8]. Given that all laboratories included in 
the harmonization program used ABL1 as the reference 
gene, we evaluated how different RNA inputs (1000, 
500 and 250 ng) affected the ratios using samples from 
CML patients at Dx. In order to minimize variability, 
quantified aliquots from the same CML Dx sample were 
Table 1: For each local RT-qPCR method, the specific conversion factor, reproducibility, precision and sensitivity are reported.
Laboratory number   Last CF  95% LOA  Median   Range   LOQ   MR4.5   CF index   CV, %  Log reduction
Ref lab   0.75  0.44–1.32  0.7   0.68–0.75   0.0003   Yes   0.89   19  5.5
Lab#1   0.84  0.45–1.57  NA   NA   0.0005   Yes   NA   27  5.3
Lab#2   0.53  0.34–0.81  0.53   0.49–0.72   0.0018   Yes   1.36   18  4.7
Lab#3   0.94  0.78–1.14  0.83   0.62–0.94   0.0007   Yes   0.88   11  5.2
Lab#4   1.10  0.43–2.71  1.1   1.01–1.10   0.0018   Yes   1.0   35  4.7
Lab#5   0.76  0.50–0.78  0.74   0.63–0.76   0.0021   Yes   0.95   17  4.7
Lab#6   0.81  0.69–1.49  1.01   0.81–1.2   0.0017   Yes   1.48   23  4.8
Lab#7   0.45  0.12–1.65  NA   NA   0.0030   Yes   NA   25  4.5
Lab#8   1.72  0.89–3.37  NA   NA   UND   No   NA   33  NA
Lab#9   0.71  0.52–0.84  0.69   0.67–0.71   0.00085   Yes   0.97   9  5.1
Lab#10   0.73  0.59–0.97  0.72   0.71–0.73   0.0017   Yes   0.97   13  4.8
Lab#11   0.68  0.23–2.00  1.02   0.68–1.35   0.0004   Yes   1.98   45  5.4
Lab#12   0.40  0.35–0.44  0.72   0.40–1.10   0.0031   Yes   1.90   7  4.5
Lab#13   0.62  0.41–0.69  0.54   0.39–0.62   UND   No   0.76   24  NA
Lab#14   2.51  1.51–4.17  1.16   0.52–2.51   UND   No   0.46   32  NA
Lab#15   0.69  0.34–1.42  NA   NA   0.0030   Yes   NA   16  4.5
Lab#16   0.59  0.32–1.00  0.83   0.56–1.09   0.0019   Yes   1.95   22  4.7
Lab#17   1.21  0.88–1.59  NA   NA   0.0010   Yes   NA   13  5.0
Lab#18   0.57  0.35–0.91  0.83   0.57–1.09   0.0012   Yes   1.91   18  4.9
Lab#19   0.59  0.37–0.95  NA   NA   0.0014   Yes   NA   23  4.9
Lab#20   0.78  0.51–1.18  NA   NA   0.0012   Yes   NA   30  4.9
Lab#21   0.73  0.46–1.17  0.73   0.35–2.35   0.0016   Yes   0.48   21  4.8
Lab#22   0.59  0.50–0.68  0.93   0.59–1.58   0.0010   Yes   0.40   6  5.0
Lab#23   0.89  0.66–1.19  1.15   0.90–1.17   0.0010   Yes   1.02   19  5.0
Lab#24   1.10  0.79–1.73  1.1   0.98–1.33   0.0008   Yes   1.21   20  5.1
Lab#25   0.89  0.62–2.97  1.13   0.89–1.36   0.0012   Yes   0.65   38  4.9
Lab#26   0.85  0.50–1.46  NA   NA   0.0019   Yes   NA   23  4.7
Lab#27   0.61  0.42–0.80  1.22   0.61–1.82   0.0010   Yes   2.98   12  5.0
Lab#28   0.75  0.57–0.99  0.75   0.62–0.75   0.0014   Yes   1.0   17  4.9
Lab#29   0.95  0.82–1.66  1.53   0.79–1.55   0.00055   Yes   1.0   24  5.3
Lab#30   1.48  1.04–2.10  NA   NA   0.0013   Yes   NA   14  4.9
CF index, values between 1.33 and 0.75 are considered stable. CF, conversion factor; CV, coefficient of variation; LOA, limit of agreement;  
log reduction, maximum measurable log reduction; LOQ, limit of quantification; MR4.5, achievable (yes) or not achievable (no) 4.5 molecular 
response; NA, not available; UND, undeterminable.
6      Ruiz et al.: Programme for Harmonization to International Scale – Ph-IS
distributed to the participating laboratories. Only six 
laboratories participated at this stage. Despite being har-
monized to the IS, we observed significant variation in 
the BCR-ABL1IS ratios among participating laboratories 
(CV%: 74, 74 and 85 for 250, 500 and 1000 ng, Figure 4), 
ranging from 0.2-fold to 2.6-fold variation from the mean 
value of all laboratories. This observation is in accord-
ance with the limit of applicability of the CF, which 
should be used only for ratios included in the range of 
secondary calibrators (around 10%–0.01%). Moreover, 
comparing ABL1 and BCR-ABL1 Ct against RNA input, we 
observed that some laboratories showed different per-
formance for both genes (Figure 5). In order to elucidate 
which factors, present at Dx samples but absent in sec-
ondary calibrators, could affect qPCR performance, we 
evaluated the effect of removing possible inhibitors and 
residual DNA. We observed differences neither between 
pre- and post-purification, nor between pre- and post-
treatment with DNAse (Supplementary Figure 2). We 
further evaluated the effect of varying concentrations of 
primers and probes in the qPCR reaction. We observed 
higher variation in BCR-ABL1IS ratios with higher RNA 
input (Supplementary Figure 3).
Discussion
Despite efforts to establish standardized protocols for 
BCR-ABL1 fusion transcript quantification, there is still 



























































































































































































































































































Figure 1: Graphs showing relative mean bias for each of the 30 laboratories.
(A) Relative difference between nominal and measured IS% ratios for all calibrator levels combined (black circle). (B) Residual difference 
after CF-conversion. Error bars show 95% LOA interval.
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is carried out. In this report, we intentionally used the 
term “harmonization” to define the entire program, to 
mark a difference with respect to the concept of “stand-
ardization”; standardization is about adopting a uniform 
approach to tackle specific work; on the other hand, 
 harmonization has a broader scope than standardization, 
as it seeks equivalence of measurement results among 
different routine measurement procedures over time 
(i.e. specimen collection and handling, preanalytical pro-
cedures, harmonizing measurement results, interpreta-
tion of results in medical contexts). Harmonization should 
allow better comparability between laboratories and lead 
to the standardization of patient assessment.
Despite the fact that commercial kits commonly used 
for RT-qPCR analysis of BCR-ABL1 are supplied with a 
CF value or a unique IS-calibrator in order to correct the 
results to the IS, it is important to consider at least two 
drawbacks, when a “portable” CF is used: first, when 
using a preestablished CF, pre-analytical (e.g. white blood 
cell lysis, RNA extraction and purification) and analytical 
(e.g. PCR platform) steps are not included in the IS cali-
bration process. In our experience, such factors are criti-
cal and should be always evaluated during the calibration 
procedure. The second important weakness of using 
“portable” CF derives from the fact that IS standardization 
cannot be achieved with a CF value derived from a single 
reference sample; in our opinion, both precision (intra- 
and inter-laboratory reproducibility) and accuracy (mean 
bias relative to the IS) should be assessed across a clini-
cally appropriate interval of IS% ratios. For this reason, we 
established and validated cellular calibrators produced 
by serial dilution of the K562 Ph-positive cell line in the 
HL-60 Ph-negative cell line, following the same scheme 
used for WHO primary standards. The establishment and 
validation of the WHO primary standards and secondary 
reagents was certainly an important milestone for IS har-
monization around the world [4, 9]. In the present study, 
we show that secondary reference biological calibrators 
anchored to the WHO primary standards can decrease 
inter-laboratory variability. Log BCR-ABL1/ABL1 values 
for the same calibrators were compared between RefLab 
and local laboratories applying the Bland-Altman bias 
plot. Our results substantiate the objectives initially set 
during the establishment of the primary WHO reference 
standards, that is, to facilitate worldwide diffusion of 
the IS and improve the quality of molecular data that are 
critical for optimal patient management. Accordingly, by 
comparing the absolute value of kit-derived CF vs. CAL-
IS-derived CF in most cases, we observed a significant dif-
ference between the two values, reinforcing the concept 
that harmonization by secondary calibrators is absolutely 
necessary.
In addition to investigate the effectiveness of this 
process, a second aim of this program was to examine the 
stability of CFs over time. CF value stability within each 
laboratory is a very important parameter to ensure compa-
rability of results along time. In order to judge the stabil-
ity of each laboratory’s methodology, a CF index (ratio of 
two consecutive rounds of calibration) was calculated and 
evaluated according to its capability to achieve optimum 
concordance of results. In most cases, we obtained con-
cordant CFs, in particular when no methodology modifica-
tions were introduced since the time of the last calibration. 



































































































Figure 2: Graph showing the follow-up of 21 participating laboratories.
The CF index represents the ratio of two CFs obtained in two consecutive rounds of calibration. The gray line indicates a perfect match 
between consecutive CFs; CF indexes within 0.75–1.33 (optimal range) are considered stable (green points in the graph). Laboratories 
outside the optimal range are considered unstable.
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time and only in six of them this could be attributed to 
modifications of reagents or equipment. These data indi-
cate that CFs may be unstable in some laboratories even in 
the absence of significant changes to laboratory protocols. 
According to Branford et al. [8, 10], minor alterations to 
analytical systems may have significant impacts on the 
measurements, requiring CF recalculation. Indeed, imper-
































































































































Figure 3: Graphs showing the correlation between the threshold cycle (Ct) number and RNA input in log scale (Log RNA).
m, slope of the line; n.s., no significant difference between slopes.
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such as instrument aging, reagent lot changes, operator 
differences, etc., which might affect the stability of the 
measurements. Therefore, the stability of CF in IS labora-
tories should be monitored regularly. In daily work, con-
tinuous CF monitoring can be carried out by including 
internal QC samples in every run to determine whether 
the CF needs to be validated or not. For those laboratories 
with unstable CFs, we suggest revalidation and a rigorous 
check-up of their internal procedure to identify potential 
sources of variation, whereas those with stable CFs should 
be assessed on a yearly basis. Finally, we strongly recom-
mend to revalidate the CF every time the procedure is 
modified like introduction of a new instrument or impor-
tant methodology changes which might affect the stability 
of the measurements.
RT-qPCR assays aim to measure reliably to at least 
MR4.5, depending on the quality of the sample received 
for testing; a deep molecular response is defined as 
BCR-ABL1IS values below 0.01% IS (MR4.0) where MR4.5 
is <0.0032% IS, and MR5.0 <0.001%. BCR-ABL1 detection 
limits of MR4.0 to MR5.0 are adequate to meet the clinical 
requirements, as there is not any evidence that the detec-
tion of BCR-ABL1 below 0.001% IS could indicate any clini-
cal benefit in terms of survival advantage or a difference in 
the rate of failure events [11]. However, molecular sensitiv-
ity, precision and accuracy are extremely important para-
meters for TKI cessation studies. The CAL-IS_05  sample 
was used to validate the sensitivity and MR4.5 detection 
capability of the assays. Most of the methods successfully 
detected BCR-ABL1 in the CAL-IS_05,  demonstrating the 
capacity to quantitate extremely small amounts of BCR-
ABL1 mRNA in patient samples. However, three laborato-
ries did not reach this level of sensitivity; in these cases, 
we suggested PCR optimization guidelines to improve 
assay performance.
In order to perform accurate quantification, target 
and reference genes should perform similarly across 
different conditions. Optimization of quantitative PCR 
requires the evaluation of amplification efficiency by 
means of a standard curve for each gene. These curves are 
usually performed with DNA, such as commercial or in-
house-developed plasmids. However, the retrotranscrip-
tion (RT) step can also add significant variation because 
of differential efficiency of RT for each gene, the presence 
of inhibitors of the RT process and/or qPCR in the sample, 
and the effect of different RNA inputs during the RT step 
[12]. Therefore, evaluation of global efficiency using RNA 
samples is highly desirable.
BCR-ABL1IS ratio is intended for CML samples from 
patients under treatment. Recent reports describing the 
impact of early reduction of BCR-ABL1 transcripts from 
baseline suggest that quantification of BCR-ABL1 tran-
scripts on Dx samples could be of clinical utility [13, 14]. 
Nevertheless, for high levels of leukemic burden, results 
are less reliable because of the lack of linearity particu-
larly for laboratories using ABL1 or GUSB, as an internal 
control gene [15]. Results obtained here discourage the 
use of BCR-ABL1 transcript rate decline from baseline, 
while using ABL1 as the control gene, because BCR-
ABL1 quantification is not reliable above 10% IS when 
data are obtained from different laboratories, despite 
them belonging to a harmonization program. In order 
to reduce variability of diagnostic ratios, a lower RNA 
input (<300 ng) resulted in lower variability when alter-
ing qPCR conditions, suggesting that higher inputs of 
RNA, where larger amounts of leukemic transcripts are 
present, may imply a condition where reagents are limit-
ing factors. Alternatively, as recently reported by Dulucq 
et al. [16], BCR-ABL1 transcript decrease from month 3 to 
month 6 using ABL1 as an internal control gene can effi-
ciently identify patients (>1% IS at 6 months) at higher 
risk of event.
In conclusion, for the first time in Latin America, 
we have successfully organized a harmonization plat-
form for BCR-ABL1 measurement (www.ph-is-com). We 
identified existing flaws in BCR-ABL1 quantification 
and suggested several recommendations to improve 
 comparability between laboratories. We believe that this 






























Figure 4: Graph showing BCR-ABL1/ABL1 ratios at diagnosis for six 
methods (Met. No.) using ABL1 as an internal control gene.
Quantitative PCRs were run on five different platforms (RotorGene 
for RefLab, ABI7500 for LAB#1 and LAB#2, Cobas Z480 for LAB#3, 
Abbott 2000 for LAB#11 and LightCycler2.0 for LAB#16). Four 
laboratories (RefLab, LAB#3, LAB#11 and LAB#16) employed the 
Molecular MD kit and the included plasmid dilution series for 
standard curve construction; on the other hand, LAB#1 and LAB#2 
employed an LDT approach, with ERM-AD623 or Ipsogen plasmid 
curve, respectively. CV, coefficient of variation.
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of BCR-ABL1 detection to ensure robust laboratory diag-
nostic capacities in Latin America.
Acknowledgments: We thank Solange Staropoli (IMEX), 
Gustavo Blandón and Paola Rozo (Genetica Lab), Ruby 
Rios (UDHO), Ezequiel Zubillaga (CIBIC), Ofelia Berenguer 
(Hemagen), Gabriel Via (Biogen), Yaribeth Olmedo Pimen-
tel (Instituto Oncologico Nacional), Vanessa  Castillo (Caja 
de Seguro Social), Mariana Debus (Fundaleu),  Margarita 
Bragos (Hospital Centenario), Lorena Zanella (LEB), Clara 
Pott Godoy (Hospital Dr. Humberto J. Notti), Laura Orel-
lano (Hospital Sor Maria Ludovica), Juan Carlos Ruiz 
Cabezas (Hospital Juan Tanca Marengo – SOLCA) and 
Martín Zubieta (Hospital El Cruce).
Author contributions: M.B. and I.L. designed the 
program of harmonization. M.S.R. and M.B.S performed 
most of the experiments. M.S.R. and M.B. performed 
data analysis; all the authors contributed with technical 
support in RT-qPCR runs, reviewed the data, drafted 
parts of the manuscript and participated with helpful 
discussion. M.B. wrote the manuscript and supervised 
the entire work. All authors read and approved the final 
manuscript. All authors have accepted responsibility for 
the entire content of this manuscript and approved its 
submission.
Research funding: This work was supported by grants 
from Novartis Argentina, Fundación Mosoteguy and Fun-
dación SALES. M.B., I.L. and J.M. are researchers from 
the Consejo Nacional de Investigaciones Científicas y 
Tecnológicas of Argentina (CONICET). M.S.R. and M.B.S. 
received CONICET fellowships.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: Authors state no conflict of interest.
Ethical approval: The local Institutional Review Board 




Lab #2 Lab #3
Lab #1
















































































Figure 5: Graphs showing the correlation between the threshold cycle (Ct) number and RNA input in log scale (Log RNA) for a Dx sample.
m, slope of the line.
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